{"id":"https://genegraph.clinicalgenome.org/r/86aaf8c3-39d3-4a35-a91c-ebc81530eed6v2.0","type":"EvidenceStrengthAssertion","dc:description":"KCNA2 was first reported in relation to autosomal dominant developmental and epileptic encephalopathy (DEE) in 2015 (Pena et al., 2015, PMID: 25477152). The gene encodes the voltage-gated \"Shaker\" potassium channel, which is a member of the Kv1 subfamily and assembles into homo- or hetero-tetrameric channels (PMID: 29050392).  The mechanism for disease is heterozygous missense variants that may have either gain-of-function, loss-of-function, or mixed effect on the potassium channel activity as measured by patch clamp recording in Xenopus laevis oocytes, or heterozygous truncating variants resulting in loss of channel function (PMID: 29050392, 25751627).  The clinical presentation is variable but typically includes infantile-onset generalized and/or focal seizures  associated with developmental delay, intellectual disability, and evidence of cerebellar dysfunction such as ataxia and dysarthria (Doering et al., 2021, PMID: 33802230; Masnada et al., PMID: 29050392).  Of note, this gene has also been implicated in autosomal dominant complicated hereditary spastic paraplegia, which is not assessed in this curation since these individuals did not have epilepsy (Helbig et al., 2016, PMID: 27543892 ; Manole et al., 2017 PMID: 28032718; ).\n\nIncluded in this curation are 10 missense or nonsense variants have been reported in 17 probands from 8 publications (PMIDs: 31054490, 29050392, 27733563, 27117551, 27062609, 26648591, 25477152, 25751627). More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached.  Nearly all probands included in the curation have confirmed or assumed de novo variants. There are three recurrent de novo variants (c.890G>A (p.Arg297Gln), c.1214C>T (p.Pro405Leu), c.1120A>G (p.Thr374Ala)) that account for ~2/3 of all reported patients (PMID: 29050392). This gene-disease association is also supported by experimental evidence including biochemical function indicating a role for Kv1.2 channels in the regulation of state transitions and repetitive discharge in medium spiny neurons (PMID: 13679409) and in expression data indicating the variant is widely expressed in the CNS, including in glutamergic pyramidal cells, GABAergic interneurons, and juxtaparanodal axons, and there is co-expression with Kv1.1, which is encoded by KCNA1 (PMID: 19118165).\n\nIn summary, KCNA2 is definitively associated with autosomal dominant DEE. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/86aaf8c3-39d3-4a35-a91c-ebc81530eed6","GCISnapshot":"https://genegraph.clinicalgenome.org/r/1a825f85-585a-4086-8118-ce912d4c1469","calculatedEvidenceStrength":"Definitive","changes":[{"id":"cg:newEvidence"},{"id":"cg:classificationChange"},{"id":"cg:summaryChange"},{"id":"cg:otherTextChange"}],"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/1a825f85-585a-4086-8118-ce912d4c1469_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10005","date":"2022-05-18T13:01:46.911Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/1a825f85-585a-4086-8118-ce912d4c1469_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10005","date":"2022-05-18T13:01:59.867Z","role":"Publisher"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1a825f85-585a-4086-8118-ce912d4c1469_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/de9d1785-b429-42af-80b2-9f570d13a4b3","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/de9d1785-b429-42af-80b2-9f570d13a4b3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27117551","allele":{"id":"https://genegraph.clinicalgenome.org/r/b4f11030-eaaa-4d98-be00-720fe62355ae","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000217.3(KCNA1):c.*1522C>G","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/309172"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/de9d1785-b429-42af-80b2-9f570d13a4b3_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"From PMID 29050392: Gain-of-function with the strongest loss-of-function in combination c/w a dominant-negative amplitude reduction.  It caused a GOF effect with -20mV shift of the activation curve and a prominent decrease in current amplitude with a dominant-negative effect (Fig. 3G, H and Supplementary Table 1).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/153b70e2-f576-4618-9bc9-f8cf1a0a26ba","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/153b70e2-f576-4618-9bc9-f8cf1a0a26ba_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25751627","allele":{"id":"https://genegraph.clinicalgenome.org/r/21b9c41c-458b-4ab5-b89d-e104cdd3ef37","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004974.4(KCNA2):c.1214C>T (p.Pro405Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10575700"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/153b70e2-f576-4618-9bc9-f8cf1a0a26ba_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Dramatic reduction in current amplitude and thus a clear loss of channel function (Fig. 2c) and exert a clear dominant-negative effect on wild-type K(V) 1.2 channels when coexpressed with wild-type","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/e1a120ec-d5a8-41dc-b50a-d125d78da7c2","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e1a120ec-d5a8-41dc-b50a-d125d78da7c2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25751627","allele":{"id":"https://genegraph.clinicalgenome.org/r/9cdf44e4-6b44-4352-aba1-994ddcd56f81","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004974.4(KCNA2):c.788T>C (p.Ile263Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA199673"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/e1a120ec-d5a8-41dc-b50a-d125d78da7c2_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Dramatic reduction in current amplitude and thus a clear loss of channel function (Fig. 2c) and exert a clear dominant-negative effect on wild-type K(V) 1.2 channels when coexpressed with wild-type","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/334f57f4-abb2-46d8-8826-099949250785","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/334f57f4-abb2-46d8-8826-099949250785_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29050392","allele":{"id":"https://genegraph.clinicalgenome.org/r/9e8570e4-4881-430f-b652-485291c798d8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004974.4(KCNA2):c.878T>A (p.Leu293His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA341602939"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/334f57f4-abb2-46d8-8826-099949250785_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Functional studies using a Xenopus oocyte two-microelectrode voltage clamp system indicate the variant displays both GOF and LOF effects and showed hyperpolarizing shifts of the activation curves (Fig. 1A and 3D), predicting a gain-of-function effect with permanently open mutant channels under physiological conditions. The variant also yielded significantly larger current amplitudes (Fig. 3A and C)","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/90a3e2e1-b79b-4eec-976d-0291b45abb00","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/90a3e2e1-b79b-4eec-976d-0291b45abb00_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25751627","allele":{"id":"https://genegraph.clinicalgenome.org/r/8ca65a64-5f19-4a34-9ce9-01495f2f6398","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004974.4(KCNA2):c.890G>A (p.Arg297Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA199675"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/90a3e2e1-b79b-4eec-976d-0291b45abb00_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Patch-clamp experiments in Xenopus laevis indicated R297Q is a GOF mut that increased current amplitudes and induced a negative shift in the channel activation curve compared to WT","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/cc5ca28b-e056-44c1-9008-e3a3d9cb5296","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cc5ca28b-e056-44c1-9008-e3a3d9cb5296_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26648591","allele":{"id":"https://genegraph.clinicalgenome.org/r/7357fd3f-996e-4c71-8c8a-2c39fef0ee6d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004974.4(KCNA2):c.869T>C (p.Leu290Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/426735"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/cc5ca28b-e056-44c1-9008-e3a3d9cb5296_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"From PMID 29050392: functional studies using a Xenopus oocyte two-microelectrode voltage clamp system indicate the variant displays both GOF and LOF effects and showed hyperpolarizing shifts of the activation curves for L290R (Fig. 1A and 3D), predicting a gain-of-function effect with permanently open mutant channels under physiological conditions. The variant also yielded significantly larger current amplitudes (Fig. 3A and C)","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/4cb2e058-d330-42e1-a013-153cd7f3d0da","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4cb2e058-d330-42e1-a013-153cd7f3d0da_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29050392","allele":{"id":"https://genegraph.clinicalgenome.org/r/d1d8ca8f-5840-4886-ab82-eb0d3bb14a6e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004974.4(KCNA2):c.1120A>G (p.Thr374Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/559647"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/4cb2e058-d330-42e1-a013-153cd7f3d0da_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Gain-of-function with the strongest loss-of-function in combination c/w a dominant-negative amplitude reduction.  It caused a GOF effect with -20mV shift of the activation curve and a prominent decrease in current amplitude with a dominant-negative effect (Fig. 3G, H and Supplementary Table 1).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/ec369a16-c1cc-45da-8fa8-5ff01158dea7","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ec369a16-c1cc-45da-8fa8-5ff01158dea7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25751627","allele":{"id":"https://genegraph.clinicalgenome.org/r/21b9c41c-458b-4ab5-b89d-e104cdd3ef37"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/ec369a16-c1cc-45da-8fa8-5ff01158dea7_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Dramatic reduction in current amplitude and thus a clear loss of channel function (Fig. 2c) and exert a clear dominant-negative effect on wild-type K(V) 1.2 channels when coexpressed with wild-type","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/3ed092a3-34e7-4d89-9113-d866dae05803","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3ed092a3-34e7-4d89-9113-d866dae05803_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25751627","allele":{"id":"https://genegraph.clinicalgenome.org/r/04cfdf49-e325-4a11-a9f2-fe3df8b84d7d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004974.4(KCNA2):c.894G>T (p.Leu298Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10575701"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/3ed092a3-34e7-4d89-9113-d866dae05803_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Strong gain of function effect with a 13-fold increase in current amplitude and a shift of âˆ’50 mV in the activation curve. As a consequence of the permanently open mutant channels, the resting membrane potentials of oocytes expressing L298F channel was about 40 mV more negative than the resting potentials of oocytes expressing wild-type channel","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/cc88fed9-b78a-44c8-a3ba-bc7895d5667a","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cc88fed9-b78a-44c8-a3ba-bc7895d5667a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25477152","allele":{"id":"https://genegraph.clinicalgenome.org/r/8ca65a64-5f19-4a34-9ce9-01495f2f6398"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/cc88fed9-b78a-44c8-a3ba-bc7895d5667a_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Patch-clamp experiments in Xenopus laevis indicated R297Q is a GOF mut that increased current amplitudes and induced a negative shift in the channel activation curve compared to WT (PMID )","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/7db23db0-fd47-4736-b8df-cf4007cdb2ad","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7db23db0-fd47-4736-b8df-cf4007cdb2ad_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29050392","allele":{"id":"https://genegraph.clinicalgenome.org/r/d1d8ca8f-5840-4886-ab82-eb0d3bb14a6e"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/7db23db0-fd47-4736-b8df-cf4007cdb2ad_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Gain-of-function with the strongest loss-of-function in combination c/w a dominant-negative amplitude reduction.  It caused a GOF effect with -20mV shift of the activation curve and a prominent decrease in current amplitude with a dominant-negative effect (Fig. 3G, H and Supplementary Table 1).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/420a28d0-54f4-4098-814c-286cb0cfeae8","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/420a28d0-54f4-4098-814c-286cb0cfeae8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29050392","allele":{"id":"https://genegraph.clinicalgenome.org/r/d1d8ca8f-5840-4886-ab82-eb0d3bb14a6e"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/420a28d0-54f4-4098-814c-286cb0cfeae8_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Gain-of-function with the strongest loss-of-function in combination c/w a dominant-negative amplitude reduction.  It caused a GOF effect with -20mV shift of the activation curve and a prominent decrease in current amplitude with a dominant-negative effect (Fig. 3G, H and Supplementary Table 1).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/f3bca39b-f8bb-4a7e-8120-304fad53eaba","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f3bca39b-f8bb-4a7e-8120-304fad53eaba_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25751627","allele":{"id":"https://genegraph.clinicalgenome.org/r/21b9c41c-458b-4ab5-b89d-e104cdd3ef37"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/f3bca39b-f8bb-4a7e-8120-304fad53eaba_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Dramatic reduction in current amplitude and thus a clear loss of channel function (Fig. 2c) and exert a clear dominant-negative effect on wild-type K(V) 1.2 channels when coexpressed with wild-type","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/0abfee46-a5f7-4686-9e5f-b9ed4db9e0e3","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0abfee46-a5f7-4686-9e5f-b9ed4db9e0e3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27733563","allele":{"id":"https://genegraph.clinicalgenome.org/r/8ca65a64-5f19-4a34-9ce9-01495f2f6398"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/0abfee46-a5f7-4686-9e5f-b9ed4db9e0e3_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"From PMID 25751627: Patch-clamp experiments in Xenopus laevis indicated R297Q is a GOF mut that increased current amplitudes and induced a negative shift in the channel activation curve compared to WT","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/ab44e57f-84c4-4198-a1ec-c5f86c43e209","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ab44e57f-84c4-4198-a1ec-c5f86c43e209_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27062609","allele":{"id":"https://genegraph.clinicalgenome.org/r/be729a58-1bc6-4c79-bcf7-efe053b315bb","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000217.3(KCNA1):c.1223T>C (p.Val408Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/13480"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/516dea1f-315f-4735-8edf-4957cebf541f","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/516dea1f-315f-4735-8edf-4957cebf541f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29050392","allele":{"id":"https://genegraph.clinicalgenome.org/r/5999ba8e-0a59-4ed3-b639-1633b1ba2db2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004974.4(KCNA2):c.637C>T (p.Gln213Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA341603549"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/ae0c0427-c5ca-41bf-bd3f-a08d193726c3","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ae0c0427-c5ca-41bf-bd3f-a08d193726c3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31054490","allele":{"id":"https://genegraph.clinicalgenome.org/r/6c76e8ab-4492-4198-ba9d-55e64da75de7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004974.4(KCNA2):c.1265_1266del (p.Glu422fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA16616953"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/1a825f85-585a-4086-8118-ce912d4c1469_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1a825f85-585a-4086-8118-ce912d4c1469_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0210e130-5ffd-46c9-8b68-fa3abe39be9d","type":"EvidenceLine","dc:description":"Used data from PMID 19118165 to show expression.  This publication shows same data - not scoring twice","calculatedScore":0.5,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4d404b66-acc1-45a1-8fef-cbb82e7079a6","type":"Finding","dc:description":"Widely expressed in mouse brain; colocalized with Kv1.1\nSee also Gtex for brain specific expression of KCNA2","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8046438","rdfs:label":"Functional Expression","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/30495407-1906-4250-b077-21191a2c6020","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ebad2678-623a-40dc-8b2d-3141da6b7c04","type":"Finding","dc:description":"Widely expressed in CNS. Increased expression in AIS along with Nav1.6 and Kv1.1. Expressed in glutamatergic pyramidal cells and GABAergic interneurons. High expression in juxtaparanodal axons. Co-expression with Kv1.1 in AIS of PCs, suggesting heteromeric channels.  See also PMID: 8046438 which also showed wide expression in mouse brain and co-localization with Kv1.1","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19118165","rdfs:label":"Functional Expression","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/057105dd-b242-4897-89d1-ffb020b62203","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0821766a-0515-4899-8c96-45d93c9e8c14","type":"Finding","dc:description":"Kv1.2 channels shown to be expressed in medium spiny neurons.  Currents attributable to Kv1.2 channels activated rapidly, inactivated slowly, and recovered from inactivation slowly. Study showed a role for Kv1.2 channels in regulating state transitions and repetitive discharge in these neurons.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/13679409","rdfs:label":"Biochemical Function","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/1a825f85-585a-4086-8118-ce912d4c1469_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9afd6ae1-3804-428c-8e81-fdedbec27ffb","type":"EvidenceLine","dc:description":"Scored as variant level evidence, not functional evidence for gene","calculatedScore":0.5,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3fc32a2c-7aa0-4ec3-b82f-065682d77ef2","type":"FunctionalAlteration","dc:description":"p.Pro405Leu variant expressed in Xenopus oocytes; co-expressed with WT Kv1.2 channels in increasing ratios (1:1; 1:2; 1:4). Current amplitudes recorded via patch clamp. Showed increasing loss-of-function, consistent with dominant-negative effect","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25751627","rdfs:label":"Cell Culture Model System.1"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/729ac0de-9caa-408a-b0f2-8940dcabdeae","type":"EvidenceLine","dc:description":"This was scored as variant-level evidence, not functional evidence for the gene","calculatedScore":0.5,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2af992ca-e924-4f96-becb-8b358bde1a5b","type":"FunctionalAlteration","dc:description":"p.Ile263Thr variant expressed in Xenopus oocytes; co-expressed with WT Kv1.2 channels in increasing ratios (1:1; 1:2; 1:4). Current amplitudes recorded via patch clamp. Showed increasing loss-of-function, consistent with dominant-negative effect","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25751627","rdfs:label":"Cell Culture Model System.2"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/53e8f7a6-fdba-4c3f-83b7-361705454904","type":"EvidenceLine","dc:description":"scored as variant level evidence, not functional evidence for gene","calculatedScore":0.5,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d63a023d-f868-4e1c-a8b0-d52fffba4b2c","type":"FunctionalAlteration","dc:description":"p.Leu298Phe variant expressed in Xenopus oocytes; co-expressed with WT Kv1.2 channels. Current amplitudes measured via patch clamp. Mean current amplitudes significantly increased compared to WT. Activation curve of WT + Leu298Phe channels significantly shifted to more hyperpolarized potentials. Resting membrane potential ~40mV more negative than WT. Consistent with constituitively open channels and GOF.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25751627","rdfs:label":"Cell Culture Model System.4"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/f3a95a2a-a0ba-4475-bdde-35277cbe6b40","type":"EvidenceLine","dc:description":"Scored as variant-level evidence, not functional evidence for gene","calculatedScore":0.5,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/79b4bf5e-a8eb-48a4-a610-80de35d6c5eb","type":"FunctionalAlteration","dc:description":"p.Arg297Gln variant expressed in Xenopus oocytes; co-expressed with WT Kv1.2 channels. Current amplitudes measured via patch clamp. Mean current amplitudes significantly increased compared to WT. Activation curve of WT + Arg297Gln channels significantly shifted to more hyperpolarized potentials. Resting membrane potential ~40mV more negative than WT. Consistent with constituitively open channels and GOF.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25751627","rdfs:label":"Cell Culture Model System.3"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/1a825f85-585a-4086-8118-ce912d4c1469_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d802176f-53ee-48f1-a411-375d593ace39","type":"EvidenceLine","dc:description":"Mouse model for ataxia, not epilepsy.  Mice had no spontaneous seizures (heterozygous for knowckout)","calculatedScore":2,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/22851f7e-8304-4c30-9651-aa608382969f","type":"Finding","dc:description":"Homozygous and heterozygous for p.I402T Kcna2 variant. Considered model for cerebellar ataxia; abnormal gait and behavior, severe post natal growth retardation (homozygous worse than heterozygous). Heterozygotes had normal life span (similar to WT). 50% of homozygotes died between 3rd and 6th weeks of life. No spontaneous seizures; heterozygotes showed no significant differences on rotarod test. Heterozygotes and homozygotes showed severe tremors, myoclonic jerks, ataxic movements.  Decreased grip strength.Treated with acetazolamide; partially rescued phenotype. I402T reduces amount of functional channels but only induces subtle changes in channel properties (CHO cell transfection); reduces density of Kv1 channel current. Increased expression of Kv1.2 partially rescues gait abnormality/coordination impairment in mouse","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20696761","rdfs:label":"Models and Rescue","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/181d052a-8edc-413b-95ea-ed86fe068af8","type":"EvidenceLine","dc:description":"Per Epilepsy GCEP SOP, can't use homozygous knockout mouse as model for AD epilepsy","calculatedScore":2,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a9e823a7-d06a-4fe2-b54b-90897e7f92e7","type":"Finding","dc:description":"Kcna2 knock out mice have spontaneous seizures with increased seizure susceptibility compared to WT and heterozygous mice. Seizure onset in neonatal period; 50% died post-seizure (stopped breathing). Neurons of the medial nucleus of the trapezoid body were hyperexcitable.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17634333","rdfs:label":"Animal Model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":1}],"evidenceStrength":"Definitive","sequence":4389,"specifiedBy":"GeneValidityCriteria5","strengthScore":13,"subject":{"id":"https://genegraph.clinicalgenome.org/r/MBswaIW4Y3I","type":"GeneValidityProposition","disease":"obo:MONDO_0100062","gene":"hgnc:6220","modeOfInheritance":"obo:HP_0000006"},"version":"2.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_1a825f85-585a-4086-8118-ce912d4c1469-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}